Moleculin Biotech
MBRX
14 hedge funds and large institutions have $315K invested in Moleculin Biotech in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 10 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
356% more capital inflows, than outflows
Capital inflows: $707K | Capital outflows: $155K
3.72% less ownership
Funds ownership: 5.51% → 1.78% (-3.7%)
30% less funds holding
Funds holding: 20 → 14 (-6)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$308K |
| 2 |
Jane Street
New York
|
+$210K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$63.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$53.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
-$61K |
| 2 |
LPL Financial
San Diego,
California
|
-$30.8K |
| 3 |
IEQ Capital
Foster City,
California
|
-$19.3K |
| 4 |
Wealth Dimensions Group
Cincinnati,
Ohio
|
-$10.6K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$7K |
MBRX Hedge Fund Activity: Q4 2025 in Review
14 of the 8,297 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2025, worth a combined $315K — down 24% from $413K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of MBRX and 4 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $308K. The largest seller was HRT Financial, exiting entirely with an estimated $61K sold.
- 14 institutional investors held Moleculin Biotech (MBRX) as of Q4 2025, down from 20 in Q3 2025.
- Funds reported $315K of Moleculin Biotech stock for Q4 2025, down 24% quarter-over-quarter.
- 4 funds opened new Moleculin Biotech positions in Q4 2025 and 10 closed out, a net change of -6 holders.
- The largest Moleculin Biotech buyer in Q4 2025 was Citadel Advisors, an estimated $308K added.
- The largest Moleculin Biotech seller in Q4 2025 was HRT Financial, an estimated $61K sold.
Based on aggregated 13F filings for Q4 2025.